Preliminary findings from a competitive evaluation study reveal the advantages of FOx Biosystems devices for biomolecular analysis during bioprocessing
Leuven, July 19, 2018 – FOx Biosystems, an innovative biosensor company, today announced its ambition to advance todays bioprocess monitoring methodologies after successfully completing a preliminary evaluation that compared different biosensor devices to monitor bioprocess related proteins.
FOx Biosystems conducted the study with the help of GSK’s biopharmaceutical team based in Stevenage, UK, who compared the FOx prototype technology with two existing biosensor technologies. Using its new White FOx 1.0 system, which uses Surface Plasmon Resonance (SPR) technology, Fox Biosystems showed that when sensitivity, reproducibility, cost per analysis and the ability to detect denaturated proteins were compared, the results showed that White FOx 1.0, is a high-performing, easy to use and cost-effective analytical instrument for biomolecular interaction analyses.
“The speed, sensitivity, cost and robustness of the FOx systems are key benefits for bioprocessing monitoring,” says Filip Delport, CTO of FOx Biosystems. “The Fiber-Optic-based surface plasmon resonance biosensor system performed very well in a blinded comparison study. Currently, our team is discussing different implementation routes to support biomolecular analysis methodologies during bioprocess development and monitoring.”
FOx Biosystems launched the White FOx 1.0 last year and renewed its strategy and focus. FOx Biosystems has the ambition to become a world-leader in the field of biomolecular analysis tools, particularly in the bioprocess monitoring field. FOx’ sensor technology can be used from µg/mL down to pg/mL in a label-free or labelled mode enabling the quantification of specific proteins, small molecules, DNA and cells in microliter volume samples. The FOx technology combines throughput with flexibility and good sensitivity in crude matrices. As such, the White FOx 1.0 has several technical benefits which expand its utility as a biomolecular interaction analysis tool for bioprocess monitoring.
Filip Delport, CTO of FOx Biosystems adds: “We are looking forward to supporting companies with bioprocess monitoring technologies. We strongly believe that our products can add value to pharmaceutical companies both in their screening stage and the bioprocess development and monitoring stage”
More information is available at www.foxbiosystems.com
About FOx Biosystems
FOx Biosystems is a spin-off from the KU Leuven. The company offers superior analytical systems, consumables and services for the R&D instrumentation market and the bioprocessing market (development and production of bio-pharmaceuticals). FOx Biosystems was founded in 2016 after more than 10 years of high level research in the MeBioS Biosensor group of Professor Lammertyn, KULeuven. The FOx Biosystems instrumentation uses the fiber optic surface plasmon resonance (FO-SPR) to detect target molecules. The disposable sensor probe is coated with a gold layer and functionalized with bioreceptors. This sensor probe is then coupled to a cost-effective, reliable analytical benchtop instrument that enables real-time analysis of biomolecular interactions with a miniaturized optical unit. This instrument, priced at a fraction of competing technologies, was designed, developed and built to be easily operated by a non-specialized user. FOx’ sensor technology can be used in a label-free or labelled mode enabling the quantification of specific proteins, small molecules, DNA and cells in microliter volume samples. This allows scientists or process control analysis laboratories to perform biomolecular analysis in a faster, more robust and more versatile way then ever before. More information is available at www.foxbiosystems.com.
FOx Biosystems Contact